Tag Archives: remicade

June, 2018

October, 2017

April, 2017

October, 2016

  • 19 October

    Pfizer Announces the US Availability of Biosimilar Inflectra

    NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE:PFE) announced today that the company will begin shipment of INFLECTRA® (infliximab-dyyb) for injection, a biosimilar of REMICADE®1 (infliximab) to wholesalers in the United States (U.S.) in late November 2016. INFLECTRA will be the first biosimilar monoclonal antibody (mAb) and only the second biosimilar to be …

September, 2016

  • 19 September

    Pfizer’s Remicade Biosimilar Candidate Succeeds in Late-Stage Study

    NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE:PFE) announced the confirmatory study (REFLECTIONS B537-02) evaluating the efficacy, safety, and immunogenicity of PF-06438179 (infliximab-Pfizer) compared to Remicade® (infliximab) met its primary endpoint. The trial demonstrated equivalent efficacy of the proposed biosimilar PF-06438179 to the originator product as measured by the American College of Rheumatology …

August, 2016

  • 30 August

    Rheumatoid Arthritis: Treatment Choices

    Early treatment for rheumatoid arthritis, studies show, pays off for patients in terms of long-term quality of life and a lower chance of later needing joint replacements. I can attest to this with a more personal perspective. Just yesterday I visited with my aunt who happens to have severe rheumatoid …

April, 2016

August, 2015

  • 21 August

    TGA Approves Hospira’s mAb Biosimilar

    MELBOURNE, Australia, Aug. 19, 2015 /PRNewswire/ — Hospira today announced that InflectraTM (infliximab), the first monoclonal antibody (mAb) biosimilar therapy, has been registered in Australia.  This registration paves the way for the Federal Government to reduce the cost of some of the most expensive medicines on the Pharmaceutical Benefits Scheme (PBS). …

July, 2015

  • 15 July

    Epirus Enters Biosimilars Collaboration with Polpharma Group

    BOSTON, July 14, 2015 (GLOBE NEWSWIRE) —  EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS) and Polpharma Group today announced the signing of a multi-product, multi-region profit-sharing collaboration for select EPIRUS biosimilars, including BOW015 (infliximab, reference biologic Remicade®), BOW050 (adalimumab, reference biologic Humira®) andBOW070 (tocilizumab, reference biologic Actemra®), representing $6 billion in innovator sales in …